Cipla Limited , a leading Indian pharmaceutical company, has announced a strategic move to strengthen its presence in the pediatric healthcare segment. The company has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences Limited, a specialized manufacturer of pediatric pharmaceutical and wellness products.

Acquisition Details

The acquisition, valued at approximately INR 110.65 crores, will be executed through a cash transaction. Here are the key details of the deal:

About Inzpera Healthsciences

Inzpera Healthsciences, incorporated in 2016, has established itself as a niche player in the pediatric pharmaceutical space. The company's financial performance over the past three years demonstrates steady growth:

Strategic Rationale

Cipla's acquisition of Inzpera Healthsciences aims to combine Inzpera's extensive portfolio of pediatric pharmaceutical and wellness products with Cipla's robust distribution network and operational capabilities. This strategic move is expected to drive growth and scalability in the pediatric healthcare segment.

Regulatory Compliance

The company has confirmed that the acquisition does not fall under related party transactions, and no governmental or regulatory approvals are required for its completion.

Future Outlook

Upon completion of the transaction, Inzpera Healthsciences will become a wholly-owned subsidiary of Cipla Limited. This acquisition aligns with Cipla's strategy to expand its product offerings and strengthen its position in specialized pharmaceutical segments.

As the pharmaceutical industry continues to evolve, strategic acquisitions like this one demonstrate how established players like Cipla are adapting to market demands and expanding their capabilities in niche areas of healthcare.

Cipla Limited , one of India's leading pharmaceutical companies, has unveiled a significant leadership transition plan set to take effect on April 1, 2026. The announcement, made on October 30, 2025, outlines key changes in the company's top management, signaling a new chapter in Cipla's corporate journey.

Leadership Transition Details

Umang Vohra, the current Managing Director and Global Chief Executive Officer (MD & GCEO), has expressed his intention not to seek re-appointment upon the completion of his term on March 31, 2026. Vohra, who has been at the helm since 2016, has played a pivotal role in Cipla's growth and strategic direction over the past decade.

Stepping into the role of MD & GCEO will be Achin Gupta, currently serving as the Global Chief Operating Officer (GCOO) of Cipla. Gupta's appointment is part of a structured succession plan developed by the Board and Vohra, aimed at ensuring continuity and a clear vision for Cipla's future.

Achin Gupta's Appointment and Background

Achin Gupta's elevation to the top position comes after a series of significant contributions to the company:

• Joined Cipla in 2021 as CEO of the One India business
• Appointed as GCOO in February 2025, overseeing Commercial markets, API, Manufacturing, and Supply Chain
• Holds an M.Tech degree from IIT Delhi and an MBA from IIM Ahmedabad
• Brings over two decades of experience as an entrepreneurial leader

Under Gupta's leadership, Cipla has seen strong growth, expanded its reach in chronic therapies and underserved geographies, and strengthened its core operations. He has been instrumental in driving market-leading profitability in the India business and forging strategic global partnerships.

Transition Timeline

To ensure a smooth transition, the following timeline has been established:

• January 1, 2026: Achin Gupta appointed as MD & GCEO Designate
• April 1, 2026: Gupta assumes full role of MD & GCEO for a term of 5 years, subject to shareholder approval

Additional Leadership Changes

In addition to the MD & GCEO transition, Cipla announced another key appointment:

• Meera Vanjari will assume the role of Global General Counsel and Senior Management Personnel, effective April 1, 2026, succeeding AS Kumar.

Board's Perspective

Dr. YK Hamied, Chairman of Cipla Limited, expressed gratitude for Umang Vohra's stewardship over the past ten years and confidence in Achin Gupta's ability to lead Cipla into its next phase of progress and growth.

Umang Vohra's Legacy

During his tenure, Vohra has been credited with:

• Driving strategic growth and financial performance
• Strengthening Cipla's global lung leadership
• Advancing digital and manufacturing capabilities
• Investing in next-generation therapies
• Maintaining top rankings across key geographies

Vohra's leadership has been characterized by a deep commitment to patient-centricity, sustainability, good governance, and talent development.

As Cipla prepares for this transition, the company reaffirms its commitment to its purpose of "Caring for Life" and combining business with a humanitarian approach. The leadership change is poised to usher in a new era of innovation and growth for one of India's most respected pharmaceutical companies.